Please login to the form below

Not currently logged in
Email:
Password:

blood cancer

This page shows the latest blood cancer news and features for those working in and with pharma, biotech and healthcare.

Roche and AbbVie prepare to move Venclexta into first-line CLL

Roche and AbbVie prepare to move Venclexta into first-line CLL

line treatment of the blood cancer in 2013.

Latest news

  • Celgene to launch five new products through to 2020 Celgene to launch five new products through to 2020

    on cancer cash-cow Revlimid. ... Looking at the quarterly figures, the standouts were Revlimid’s 18% gain, a 23% rise for blood cancer stable mate Pomalyst (pomalidomide) to $513m, and a 40% boost for Otezla to

  • CHMP delays decision on Kiadis’ GVHD immunotherapy CHMP delays decision on Kiadis’ GVHD immunotherapy

    ATIR101 is a novel cell therapy which aims to help improve outcomes in patients who receive  hematopoietic stem cell translation (HSCT) for certain types of blood cancer. ... ATIR101 aims to target this, more specifically Graft-versus-Host-Disease (GVHD)

  • China’s Innovent to start US trials of anti-CD47 cancer drug China’s Innovent to start US trials of anti-CD47 cancer drug

    Some cancer cells express CD47 at very high levels and this seems to correlate with poor survival. ... The rationale for that dual approach is that CD47 is widely distributed in healthy tissues, and targeting CD19 can help avoid potential

  • Geron poleaxed as partner J&J abandons only pipeline drug Geron poleaxed as partner J&J abandons only pipeline drug

    Johnson &Johnson has dissolved its four-year-old partnership with Geron for cancer drug imetelstat, wiping two-thirds off the biotech’s share price at a stroke. ... that form of blood cancer.

  • CRUK forges £30m ‘post-Brexit’ R&D alliance CRUK forges £30m ‘post-Brexit’ R&D alliance

    One UK project – called HUNTER - is getting £5m to look into immunotherapies for liver cancer and will be led by Newcastle University. ... The University of Trento is leading on a project worth around £5m to develop a blood test for advanced prostate

More from news
Approximately 9 fully matching, plus 217 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... Breast cancer drug Ibrance will be one of the biggest growth drivers for the company, as it looks

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

  • Taking a strategic approach Taking a strategic approach

    proposed submitting further evidence and an amended patient access scheme for its prostate cancer drug. ... In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    485. AstraZeneca/Celgene. Exclusive collaboration. MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers. ... 85. Agios Pharmaceuticals / Celgene. R&D collaboration and profit share. AG-881 IDH (isocitrate dehydrogenase) mutant

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    Increasing the speed of knowledge sharing in blood cancer to improve patient care. ... Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities.

  • Increasing the speed of knowledge sharing in blood cancer to improve patient care

    Increasing the speed of knowledge sharing in blood cancer to improve patient care. ... Spring has sprung and the blood cancer congress calendar is jam-packed with news, science, education and knowledge sharing opportunities.

  • THE OTHER SIDE OF...BLOOD CANCER

    participant. THE OTHER SIDE OF … BLOOD CANCER. “ I’ m so sick of chasing him down the hospital corridors. ... The environment is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’ s time is limited.

  • THE OTHER SIDE OF...BLOOD CANCER

    participant. THE OTHER SIDE OF … BLOOD CANCER. “ I’ m so sick of chasing him down the hospital corridors. ... The environment is certainly one challenge – busy hospital, many blood cancer patients, so her doctor’ s time is limited.

  • Cancer communications; it's in our blood

    Cancer communications; it's in our blood. We have years of experience working in cancer communications, partnering with some of the biggest brands, institutions and societies. ... From solid tumours to blood cancer, from patients to professionals; within

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics